TrialPath
Recruiting

Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis

NCT05278520 · University of Turku
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
About this study
The specific objectives of this project are: 1. Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B focusing on the inflammatory responses, D) determine what are the key molecular pathways activated in OA. 2. To determine if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA. 3. To map the whole transcriptome and proteome of OA and non-arthritic control tissue while keeping the morphological context with spatial omics technologies. 4. Further differentiation and identification of OA endotypes utilizing the single-cell and spatial omics data. The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.
Eligibility criteria
Inclusion Criteria for the main (OA) study: Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty. Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty. \---- Inclusion Criteria for the Rheumatoid sub-study: Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty. \---- Exclusion Criteria: * The body mass index must be below 35 * Age \< 18 or \> 74 * The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome. For the Rheumatoid sub-study, the exclusion criteria are the same as above except for the RA.
Study design
Enrollment target: 110 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-01-11
Estimated completion: 2028-12
Last updated: 2025-08-24
Interventions
Procedure: Total hip arthroplasty
Primary outcomes
  • Characterization of cell populations in OA (Starting during the first quarter of 2025, ending by the last quarter of 2026.)
  • Comparison of cell populations between OA cases and controls (Starting during the first quarter of 2025, ending by the last quarter of 2026.)
  • Cellular landscape in OA (Starting during the last quarter of 2024, ending by the last quarter of 2026.)
Sponsor
University of Turku · other
With: Turku University Hospital, Hospital District of Helsinki and Uusimaa
Contacts & investigators
ContactLea Mikkola, PhD · contact · limikk@utu.fi · +358404143300
InvestigatorLea Mikkola, PhD · principal_investigator, Turku Bioscience, University of Turku
All locations (4)
PET-centre, University of TurkuActive Not Recruiting
Turku, Southwest Finland, Finland
Turku Bioscience, University of TurkuActive Not Recruiting
Turku, Southwest Finland, Finland
Turku University HospitalRecruiting
Turku, Southwest Finland, Finland
Helsinki University HospitalRecruiting
Espoo, Uusimaa, Finland